R&D Cutbacks Unlikely Under Any Medicare Plan, AARP's Smith Says

Pharmaceutical companies are not likely to scale back R&D, even if a Medicare drug benefit affects the profitability of manufacturers, AARP Director for Health Issues Patricia Smith suggested during an Alliance for Health Reform briefing April 20 in Washington, D.C.